Compare Amgen, Inc. (AMGN) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Ulta Beauty Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Ulta Beauty Inc trades at $469.2 (market cap $20.17B). The key difference: Amgen, Inc. is far larger — about 9.7× Ulta Beauty Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| AMGN | ULTA | |
|---|---|---|
Market Cap | $196.12B | $20.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $706.82 |
52-Week Low | $271.18 | $450.75 |
Enterprise Value | $241.41B | $22.25B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ULTA Beauty trades at $469.20, up 1.95% on the day, with a bearish technical signal but strong fundamentals including a 9.36% net income margin and 47.45% ROE. Recent Q1 2026 earnings beat expectations at $7.74 EPS versus $6.89. The stock is near its pivot point of $457, with resistance at $470. Positive news highlights international expansion and a robust loyalty program driving 95% of sales.
The outlook is mixed: analyst consensus is bullish with a $623.73 price target, but technicals and recent net cash flow negativity pose risks. Investment opportunity lies in market share gains and AI-driven personalization, while headwinds include competitive pressures and margin compression from 11.42% in 2022 to 9.35% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
